Benzinga - by Lisa Levin, Benzinga Editor.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates.
Vertex Pharmaceuticals posted adjusted earnings of $4.08 per share, beating market estimates of $3.98 per share. The company’s quarterly sales came in at $2.48 billion versus expectations of $2.50 billion.
Vertex said it now sees FY23 sales of around $9.85 billion from its CF treatments.
Vertex shares fell 0.6% to trade at $383.51 on Tuesday.
These analysts made changes to their price targets on Vertex Pharmaceuticals following earnings announcement.
- HC Wainwright & Co. raised the price target on Vertex Pharmaceuticals from $ $380 to $390. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating.
- Stifel increased the price target on Vertex Pharmaceuticals from $340 to $373. Stifel analyst Paul Matteis maintained a Hold rating.
- Cantor Fitzgerald raised the price target on Vertex Pharmaceuticals from $370 to $380. Cantor Fitzgerald analyst Olivia Brayer maintained an Overweight rating.
- BMO Capital raised the price target on Vertex Pharmaceuticals from $389 to $415. BMO Capital analyst Evan Seigerman maintained an Outperform rating.
- RBC Capital cut the price target on Vertex Pharmaceuticals from $350 to $347. RBC Capital analyst Brian Abrahams maintained a Sector Perform rating.
Latest Ratings for VRTX
Feb 2022 | RBC Capital | Downgrades | Outperform | Sector Perform |
Jan 2022 | BMO Capital | Upgrades | Market Perform | Outperform |
Dec 2021 | Wells Fargo | Initiates Coverage On | Overweight |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.